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Durability of Benefits From Supervised Treadmill Exercise in People
With Peripheral Artery Disease
Mary M. McDermott, MD; Melina R. Kibbe, MD; Jack M. Guralnik, MD, PhD; Luigi Ferrucci, MD, PhD; Michael H. Criqui, MD, MPH;
Kathryn Domanchuk, BS; Lu Tian, ScD; Lihui Zhao, PhD; Lingyu Li, MS; Kruti Patel, BA; Tamar S. Polonsky, MD
Background-—It is currently unknown whether 6 months of supervised treadmill exercise has a durable benefit on 6-minute walk
performance, even after exercise is completed, in people with peripheral artery disease.
Methods and Results-—A total of 156 participants with peripheral artery disease were randomized to 1 of 3 groups: supervised
treadmill exercise, supervised resistance training, or attention control. Participants received supervised sessions during months 1 to 6
and telephonecontact duringmonths6 to 12. Primary outcomeswere change in6-minutewalk distance and short physical performance
battery at 6-month follow-up and have been reported previously. Secondary outcomeswere change in 6-minute walk and short physical
performancebattery at 12-month follow-up and are reported here. A group of 134participants (86%) completed the12-month follow-up.
At 6-month follow-up, compared with control, 6-minute walk distance improved in the treadmill exercise group (+36.1 m, 95% CI=13.9-
58.3, P=0.001). Between 6- and 12-month follow-up, 6-minute walk distance significantly declined (28.6 m, 95% CI=52.6 to4.5,
P=0.020) and physical activity declined272 activity units (95% CI=546 to +2, P=0.052) in the treadmill exercise group compared
with controls. At 12-month follow-up, 6 months after completing supervised treadmill exercise, change in 6-minute walk distance was
not different between the treadmill exercise and control groups (+7.5, 95% CI=17.5 to +32.6, P=0.56). There were no differences in
short physical performance battery change between either exercise group and control at 6-month or 12-month follow-up.
Conclusions-—A 6-month supervised treadmill exercise intervention that improved 6-minute walk distance at 6-month follow-up
did not have persistent benefit at 12-month follow-up. These results do not support a durable benefit of supervised treadmill
exercise in peripheral artery disease.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov. Identifier: NCT00106327. ( J Am Heart Assoc. 2019;8:
e009380. DOI: 10.1161/JAHA.118.009380.)
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S upervised treadmill exercise significantly improves walkingendurance in people with lower extremity peripheral artery
disease (PAD).1-4 In 2017 Medicare announced a decision to
cover 12 weeks of supervised treadmill exercise for patients
with symptomatic PAD.5 In providing this coverage, Medicare
assumed that 12 weeks of supervised treadmill exercise would
have a durable benefit for patients with PAD, even after the
supervised exercise therapy was completed.5 However, rela-
tively few data exist regarding the durability of benefit from
supervised treadmill exercise for patients with PAD.
SILC (theStudy to Improve LegCirculation)was a randomized
trial of 6 months of supervised treadmill exercise and super-
vised resistance training in people with PAD.3 SILC demon-
strated that supervised treadmill exercise, but not supervised
resistance training, significantly improved the 6-minute walk at
6-month follow-up, compared with a control group.3 The current
report describes changes in 6-minute walk and other study
outcomes at 12-month follow-up, 6 months after the exercise
interventions were completed. The tested hypothesis was that,
in people with PAD, the 6-month supervised treadmill exercise
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intervention would have a durable effect on 6-minute walk
performance and the short physical performance battery (SPPB)
at 12-month follow-up, 6 months after the supervised treadmill
exercise intervention was completed.
Methods
The institutional review boards of participating sites approved
the protocol. Participants gave written informed consent. The
study design was a randomized clinical trial.3,6 Participants
were randomized to 1 of 3 groups: supervised treadmill
exercise, supervised lower extremity resistance training, or an
attention control group.3,6 Data collection and study inter-
ventions were performed at Northwestern University Feinberg
School of Medicine between April 1, 2004 and August 19,
2008. The data supporting the findings of this study are
available from the corresponding author on reasonable
request, within constraints allowed by the institutional review
board.
Participant Identification
Participants were recruited from newspaper and radio
advertisements, noninvasive vascular laboratories and clinics
at Chicago-area hospitals, mailings to Chicago residents aged
60 and older, posted flyers, recruitment mailings to people
identified with a low ankle-brachial index (ABI) in the Lifeline
of Screening program, and community outreach methods.6
Inclusion and Exclusion Criteria
The inclusion criterion was an ABI ≤0.95.3,7 Because most
people with PAD do not have classical symptoms of
intermittent claudication,8-10 PAD participants without classi-
cal intermittent claudication were included to increase
generalizability of results.
Exclusion criteria were dementia, critical limb ischemia,
foot ulcers, major amputation, nursing home residence,
inability to attend exercise sessions 3 times weekly, inability
to walk on a treadmill, failure to complete exercise run-in
sessions, major surgery, a myocardial infarction within the
past 3 months, major surgery planned in the next year,
current participation in other clinical trials, already exercising
at a level comparable to that offered in either exercise arm,
abnormal baseline exercise stress test, walking limitation
from a cause other than PAD, poorly controlled hypertension,
and a baseline SPPB score of 12 (ie, maximal possible score).
Ankle Brachial Index Measurement
A hand-held Doppler probe (Nicolet Vascular Pocket Dop II;
Nicolet Biomedical Inc, Golden, CO) was used to obtain
systolic pressures in the right and left brachial, dorsalis pedis,
and posterior tibial arteries.7,11,12 Each pressure was mea-
sured twice. The ABI was calculated by dividing the mean of
the dorsalis pedis and posterior tibial pressures in each leg
by the mean of the 4 brachial pressures.11 Average pressures
in the arm with the higher pressure were used when 1 brachial
pressure was higher than the opposite brachial pressure in
both measurement sets and the 2 brachial pressures differed
by ≥10 mm Hg in 1 measurement set.11,12
Outcomes
Outcomes were measured at baseline and at 6-month and 12-
month follow-up after randomization. Outcome assessors were
blinded to participants’ group assignments. Change in the 6-
minute walk test and the SPPB at 6-month follow-up were the
primary outcomes.3,13-15 Physical activity, measured by Caltrac
accelerometer, was a secondary outcome.16-18 Exploratory
outcomes were the Walking Impairment Questionnaire (WIQ)
and the Short-Form 36 (SF-36) physical functioning score.19,20
Six-Minute Walk
The 6-minute walk test is a well-validated measure of walking
endurance in people with PAD that is similar to the type of
corridor walking required in daily life.13 The 6-minute walk test
was the primary outcome for the following reasons. First,
because the 6-minute walk is performed in a hall corridor, it is
directly relevant to the type of walking that people with PAD
engage in during daily life.13 In contrast, treadmill walking is
performed on a moving belt and does not represent the type of
walking typically encountered in daily life. Second, among
people with PAD, 6-minute walk performance correlates better
Clinical Perspective
What Is New?
• Among people with lower-extremity peripheral artery dis-
ease, 6-minute walk distance significantly declined during
the 6-months following completion of a supervised treadmill
exercise intervention.
• Supervised treadmill exercise did not have a durable effect
on improving walking endurance, measured by 6-minute
walk distance, in people with peripheral artery disease.
What Are the Clinical Implications?
• Supervised treadmill exercise may not have a durable
benefit in people with peripheral artery disease.
• Additional medical interventions may be necessary to
achieve sustained improvement in walking endurance after
supervised treadmill exercise in people with peripheral
artery disease.
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with physical activity during life than treadmill walking
performance.15 Third, treadmill walking performance, but not
the 6-minute walk, is associated with a significant learning
effect.13 Fourth, a minimum clinically important difference has
been defined for the 6-minute walk test,21 but it has not been
defined for treadmill-walking performance.13 Fifth, the 6-minute
walk is well validated in people with PAD and predicts mobility
loss and mortality.22,23 Greater decline in the 6-minute walk
predicts higher rates of mobility loss and mortality.24 Sixth, 6-
minute walk performance correlates with PAD severity.25
Seventh, 6-minute walk distance improves in response to
supervised treadmill exercise interventions and in response to
home-based walking interventions in PAD.3,4,26 Because the
SILC randomized trial tested a treadmill exercise intervention,
and the treadmill-walking measurement is known to have a
learning effect that may be exaggerated by the treadmill
intervention, the 6-minutewalk test was selected as the primary
outcome to avoid a learning effect for the outcome of walking
endurance.
Following a standardized protocol,3,4,13,15 participants
walked up and down a 100-foot hallway for 6 minutes after
standardized instructions to cover as much distance as
possible. Participants were allowed to rest if needed, but the
stopwatch continued during rest periods. The distance
completed after 6-minutes was recorded. The intraclass
correlation coefficient for test-retest reliability of the 6-
minute walk was 0.90 (P<0.001) among 155 PAD partici-
pants in our laboratory who completed 2 tests 1 to 2 weeks
apart.13,15
Short Physical Performance Battery
The SPPB combined data from the usual paced 4-m walking
velocity, time to rise from a seated position 5 times, and
standing balance.3,14 Individuals received a 0 score for each
task they were unable to complete. Scores of 1 to 4 were
assigned for the remaining tasks, according to established
methods.3,14 Scores were summed to obtain the SPPB,
ranging from 0 to 12.3,14 The test-retest reliability of the SPPB
was 0.77 (P<0.001) among 151 PAD participants in our
laboratory who completed 2 tests 1 to 2 weeks apart.3
Repeated Chair Rises
Participants stood from a seated position in a straight-backed
chair 5 times as quickly as possible without using their arms.
Time to complete 5 chair rises was measured.3,14
Standing Balance
Participants were asked to hold 3 increasingly difficult
standing positions for 10 seconds each: the side-by-side
stand, semitandem stand (feet parallel and heel of 1 foot
touching the base of the first toe of the opposite foot), and
the full tandem stand (standing with 1 foot directly in front of
the other).3,14 Scores ranged from 0 (unable to hold the side-
by-side stand for 10 seconds) to 4 (able to hold the full
tandem stand for 10 seconds).
Four-Meter Walking Velocity
Walking velocitywasmeasuredwith a4-mwalk performedat the
usual pace, according to previously described methods.3,14
Physical Activity
Physical activity was measured continuously for 7 days using
a vertical accelerometer (Caltrac, Muscle Dynamics Fitness
Network, Inc, Torrance, CA) according to established meth-
ods, yielding “activity units.”16-18
Quality of Life
The WIQ is a PAD-specific measure of self-reported walking
limitations with 3 domains: walking distance, walking speed,
and stair climbing.19 Each domain is scored on a 0-to-100
scale on which 0 represents the most extreme limitation and
100 represents no difficulty walking long distances, walking
rapidly, or climbing 3 stair flights, respectively.19 We used the
Medical Outcomes Study SF-36 to assess functional status in
the physical functioning domain.20
Randomization
Eligible participants were randomized using block randomiza-
tion with block size randomly chosen from 6 and 9. Random-
ization was stratified by the presence versus absence of
intermittent claudication.
Interventions
During months 1-6, participants attended on-site sessions.
During months 7-12, no on-site sessions were provided, and
all contact with participants was by telephone. Content of the
telephone calls varied according to group assignment as
described below. All participants were telephoned once per
week during month 1, every other week during months 2-3,
and once per month in months 4-6.
Supervised Treadmill Exercise
The supervised treadmill exercise intervention consisted of
treadmill exercise 3 times weekly for 6 months, supervised by
an exercise physiologist. Participants began with 15 minutes
of exercise and increased to 40 minutes of exercise per
session.3 After week 8, exercise intensity was increased at
least weekly either by increasing treadmill speed or by
increasing treadmill grade. Participants were encouraged to
exercise to near-maximal leg symptoms.
DOI: 10.1161/JAHA.118.009380 Journal of the American Heart Association 3
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Between months 6 and 12, participants were telephoned
by the exercise physiologist and encouraged to continue
walking exercise. During this phase of the study, supervised
sessions were not available, and exercise recommendations
were individualized. Participants with access to a treadmill
were encouraged to use the treadmill for exercise. Partici-
pants without access to a treadmill were encouraged to walk
for exercise outside or at another venue, according to their
preferences.
Supervised Lower-Extremity Resistance Training
Participants in the lower-extremity resistance-training group
exercised 3 times weekly for 6 months with a trainer.
Participants performed 3 sets of 8 repetitions of knee-
extension, leg-press, and leg-curl exercises using standard
equipment. For each exercise, the 1 repetition maximum
was measured at baseline and subsequently every 4 weeks.
Participants began exercising at 50% of their 1 repetition
maximum and increased to 80% of their 1 repetition
maximum during the first 5 weeks of exercise training.
Weights were adjusted after each monthly 1 repetition
maximum and as needed to achieve an exercise intensity
consistent with a rate of perceived exertion of 12 to 14.
Participants also performed 3 sets of 8 repetitions of squat
and toe-rise exercises.
Between months 6 and 12, participants were provided with
ankle weights and instructed on lower extremity resistance
exercises with the ankle weights to perform at home.
Attention Control, Months 1 to 6
The attention-control group was designed to ensure that
participants not randomized to exercise received regular atten-
tion from study staff. The attention control group attended 11
1-hour group sessions over a 6-month period, during which a
registered dietician provided information regarding nutritional
supplements, healthy restaurant eating, and increasing fruit and
vegetable consumption.Duringmonths6 to12, participantswere
telephoned by the registered dietician, and nutrition information
previously provided during on-site sessions was reviewed.
Leg Symptoms
Leg symptoms were characterized using the San Diego
claudication questionnaire.9,27 Based on prior study, intermit-
tent claudication was defined as exertional calf pain that did
not begin at rest, caused the participant to stop walking, and
resolved within 10 minutes of rest.9,27 Participants without
intermittent claudication were classified either as asymp-
tomatic if they had no exertional leg symptoms or with
atypical ischemic leg symptoms if they had exertional leg
symptoms not consistent with intermittent claudication
(9.27).
Additional Measures
Medical history, race, and demographics were obtained using
a standardized data collection form. Body mass index was
calculated based on height and weight measures obtained at
the study visit.
Power Considerations
The a priori sample size calculation was as follows. At 12-
month follow-up, 6 months after the supervised interventions
were completed, a sample size of 50 participants in each
group provided 80% power to detect a difference of 30.2 m in
mean change of 6-minute walk distance and a difference of
0.97 in mean change in the SPPB score between each
exercise group and the control group. For the 6-minute walk, a
small meaningful difference consists of 20 m, and a large
meaningful difference consists of 50 m.21 For the SPPB, a
small meaningful difference consists of 0.50 point and a large
meaningful difference consists of 1.0 point.21
Statistical Analyses
Intention-to-treat analyses were performed. Chi-squared tests,
Fisher exact test, and 1-way analyses of variance were used
to compare characteristics of participants across the 3 groups
at baseline. For the outcomes of 6-minute walk, SPPB, and
Caltrac physical activity, 2-sample, 2-sided t tests were used
to compare changes in outcomes between baseline and 6-
month follow-up, between 6- and 12-month follow-up, and
between baseline and 12-month follow-up between each
exercise group and the control group, respectively. Because
distributions of remaining outcomes (ie, WIQ scores) were
skewed, median values and interquartile ranges were used to
summarize cross-sectional distributions and changes for
remaining outcomes. The between-group comparisons for
these outcomes were based on 2-sided Hodge-Lehman tests,
which did not require the normal assumption. The within-
group change was evaluated using a 1-sample Wilcoxon rank
test. Missing data were imputed for participants who attended
a 12-month follow-up visit but were missing data for at least 1
outcome at any of the visits, using multiple imputation (SAS
Proc MI; SAS Institute, Cary, NC) and generating 20 imputed
data sets. Variables used for imputation were treatment
assignment, age, ABI, body mass index, sex, race, smoking
status, leg symptoms, comorbidities, and study outcomes at
baseline, 6-month follow-up, and 12-month follow-up. Corre-
sponding comparisons between groups were based on 2-
sample, 2-sided t tests or Hodge-Lehman tests, based on the
imputed data sets. A priori, the P value considered statistically
significant was P<0.05. Analyses were performed using SAS
version 9.4.
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Results
Of 156 participants with PAD randomized, 144 (92%)
completed 6-month follow-up testing, and 134 (86%)
completed 12-month follow-up testing (Figure 1). Partici-
pants who did not complete 12-month follow-up testing had
higher prevalences of heart failure and current smoking
compared with those who completed 12-month follow-up
testing (Table 1).
Among participants who completed 12-month follow-up
testing, the mean age of participants was 70.7 (SD=10.4), 61
(46%) were male, and 53 (40%) were black; mean ABI was
0.61 (SD=0.17). The prevalence of blacks was lowest among
participants randomized to strength training and highest
Assessed for eligibility 
(n=746) Excluded (n=590)
Not meeting inclusion criteria
(n=261)
Refused participation
(n=80)
Other reasons 
(n=249)
Allocated to resistance training
(n=52)
6-month Follow-Up
Analyzed (N=46)
Lost to follow-up (n=6)
Give reasons: Participant 
refused follow-up testing (n=5), 
death (n=1)
Discontinued intervention (n=3)
Give reasons: Medical leave
(n=1), lost interest (n=2)
Analyzed (N=48)
Lost to follow-up (n=5)
Give reasons: Participant 
refused follow-up testing (n=4), 
death (n=1)
Analyzed (N=50)
Lost to follow-up (n=1)
Give reasons: Participant refused 
follow-up testing (n=1)
Discontinued intervention (n=3)
Had myocardial infarction (n=1), 
lost interest (n=2)
12-month follow -up
Analyzed (n= 47)
Excluded from analysis (n=4)
Give reasons: Participant 
refused follow-up testing (n=4)
Analyzed (n=44)
Excluded from analysis (n=8)
Give reasons: Participants
refused follow-up testing (n=7), 
death (n=1)
Analyzed (n=43)
Excluded from analysis (n=10)
Give reasons: Participants
refused follow-up testing (n=8), 
death (n=2)
Enrollment
Randomized 
(n=156)
Random
Allocation
Allocated to supervised 
treadmill (n=51)
Allocated to attention control
(n=53)
Figure 1. Study participation and follow-up rates.
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among participants randomized to the control group. There
were no other differences in characteristics across the 3
groups (Table 2). Although rates of successful telephone
contact between the exercise physiologist and the participant
were not systematically tracked, the proportions of success-
fully completed monthly telephone calls to ascertain serious
adverse events were 86.9% in the treadmill-exercise group,
84.5% in the strength-trained group, and 83.7% in the control
group.
The 6-month supervised treadmill exercise intervention
significantly improved the 6-minute walk distance at 6-month
follow-up, compared with control (+36.1 m, 95%CI +13.9-
58.3, P=0.001). However, at 12-month follow-up, 6 months
after the supervised treadmill exercise intervention had been
completed, there was no difference in change in 6-minute walk
distance from baseline between people randomized to super-
vised treadmill exercise and those randomized to the control
group (+7.5 m, 95%CI 17.5 to +32.6, P=0.56) (Table 3).
During the 6 months after the supervised treadmill exercise
intervention had been completed, between 6- and 12-month
follow-up, the 6-minute walk significantly declined in the
treadmill exercise group (within-group change 24.6 m, 95%
CI 41.2 to 8.0, P=0.004; between-group change compared
with the control group was 28.6 m, 95%CI 52.6 to 4.5,
P=0.020) (Table 4, Figure 2). There was no effect of the
supervised treadmill exercise intervention on change in the
SPPB at any follow-up time point (Tables 3 and 4).
The supervised treadmill exercise intervention significantly
improved the WIQ distance score at 6-month follow-up
(median-+15.0, 95%CI, +6.1 to +23.9, P=0.001). However,
at 12-month follow-up, 6 months after completion of the
treadmill exercise intervention, there were no significant
effects of the treadmill exercise intervention on any WIQ
scores compared to the control group (Table 3). During the 6
months after the supervised treadmill exercise intervention
had been completed, between 6- and 12-month follow-up, the
WIQ distance score declined in the treadmill exercise group
compared with the control group, but the difference did not
quite reach statistical significance (8.8, 95%CI 18.3 to
+0.6, P=0.066) (Table 4).
The 6-month supervised treadmill exercise intervention
improved the SF-36 physical functioning score at 12-month
follow-up (+10.0, 95%CI +0.7 to 19.3, P=0.035) compared
with the control group (Table 3). The supervised exercise
intervention did not improve physical activity at 12-month
follow-up, compared with the control group (Table 3).
There were no significant effects of the resistance
training intervention on any study outcome at 12-month
follow-up.
Results did not substantially change when the 8 partici-
pants (5.9%) who had reported no exertional leg symptoms at
baseline (ie, asymptomatic participants) were excluded from
analyses (data not shown). However, after exclusion of the 8
PAD participants who were asymptomatic, compared with
Table 1. Characteristics of Participants With Versus Without 12-Month Follow-Up Data
Baseline Measures Total Randomized (N=156)
Completed 12-Mo
Follow-Up Testing (N=134)
Did Not Complete 12-Mo
Follow-Up Testing (N=22)
Age (y), mean (SD) 70.6 (10.3) 70.7 (10.4) 70.1 (9.6)
Male, n (%) 75 (48.1) 61 (45.5) 14 (63.6)
Black, n (%) 62 (39.7) 53 (39.6) 9 (40.9)
Ankle brachial index, mean (SD) 0.61 (0.17) 0.61 (0.17) 0.62 (0.20)
Body mass index (kg/m2), mean (SD) 30.2 (6.8) 30.1 (6.7) 30.9 (7.4)
Current smoker, n (%) 37 (23.7) 28 (20.9) 9 (40.9)
Angina, n (%) 18 (11.8) 15 (11.5) 3 (13.6)
Myocardial infarction, n (%) 34 (22.1) 28 (21.2) 6 (27.3)
Heart failure, n (%) 21 (13.6) 13 (9.8) 8 (36.4)
Stroke, n (%) 32 (20.8) 26 (19.5) 6 (28.6)
Pulmonary disease, n (%) 20 (13.0) 15 (11.3) 5 (23.8)
Cancer, n (%) 28 (17.9) 24 (17.9) 4 (18.2)
Diabetes mellitus, n (%) 69 (44.2) 58 (43.3) 11 (50.0)
Knee arthritis, n (%) 48 (31.2) 44 (33.3) 4 (18.2)
Hip arthritis, n (%) 28 (18.7) 26 (20.2) 2 (9.5)
Classical intermittent claudication symptoms, n (%) 56 (35.9) 49 (36.6) 7 (31.8)
Asymptomatic, n (%) 11 (7.1) 8 (6.0) 3 (13.6)
DOI: 10.1161/JAHA.118.009380 Journal of the American Heart Association 6
Durability of Supervised Exercise Benefits in PAD McDermott et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
control, physical activity levels significantly declined between
6- and 12-month follow-up in those randomized to supervised
treadmill exercise (285 m, 95%CI 570 to 1, P=0.0496).
Results were largely unchanged when analyses were per-
formed separately among participants with intermittent
claudication and among those without intermittent claudica-
tion symptoms. However, among participants with intermit-
tent claudication, the difference between the supervised
treadmill exercise group and controls in decline in 6-minute
walk distance between 6- and 12-month follow-up was no
longer statistically significant (21.6 m, 95%CI 58.6 to
+15.4), perhaps due to the small sample size in this group
(N=49). In addition, among participants without classical
symptoms of intermittent claudication, there was no differ-
ence in the SF-36 physical functioning score between the
supervised treadmill exercise and control groups at 12-month
follow-up (+6.3, 95%CI 6.2 to +18.7, P=0.32), and the WIQ
distance score declined significantly in the supervised tread-
mill exercise group compared with controls between 6- and
12-month follow-up (12.4, 95%CI 24.4 to 0.5, P=0.042).
Nonimputed results for data in Tables 3 and 4 are shown in
Tables S1 and S2.
Discussion
In the primary results for this randomized clinical trial of
participants with PAD, 6 months of supervised treadmill
exercise significantly improved the 6-minute walk distance at
6-month follow-up compared with a control group.3 However,
the 6-minute walk distance significantly declined during the
6 months after supervised exercise had ended. Twelve
months after baseline (6 months after the supervised tread-
mill exercise intervention had been completed), there was no
significant difference in change in the 6-minute walk distance
Table 2. Baseline Characteristics According to Group Assignment*
Baseline Measures Overall (N=134) Control (N=43) Strength (N=44) Treadmill (N=47)
Age (y), mean (SD) 70.7 (10.4) 68.1 (12.2) 71.8 (10.2) 72.0 (8.5)
Male, n (%) 61 (45.5) 19 (44.2) 22 (50.0) 20 (42.6)
Black, n (%) 53 (39.6) 22 (51.2) 11 (25.0) 20 (42.6)
Ankle brachial index, mean (SD) 0.61 (0.17) 0.60 (0.18) 0.62 (0.15) 0.60 (0.17)
Body mass index (kg/m2), mean (SD) 30.1 (6.7) 30.5 (7.5) 29.7 (6.5) 30.2 (6.1)
Current smoker, n (%) 28 (20.9) 11 (25.6) 8 (18.2) 9 (19.1)
Angina, n (%) 15 (11.5) 3 (7.1) 7 (16.7) 5 (10.6)
Myocardial infarction, n (%) 28 (21.2) 5 (11.6) 12 (27.9) 11 (23.9)
Heart failure, n (%) 13 (9.8) 4 (9.3) 6 (13.6) 3 (6.7)
Stroke, n (%) 26 (19.5) 8 (18.6) 7 (15.9) 11 (23.9)
Pulmonary disease, n (%) 15 (11.3) 6 (14.3) 6 (13.6) 3 (6.4)
Cancer, n (%) 24 (17.9) 6 (14.0) 8 (18.2) 10 (21.3)
Diabetes mellitus, n (%) 58 (43.3) 18 (41.9) 20 (45.5) 20 (42.6)
Knee arthritis, n (%) 44 (33.3) 15 (34.9) 15 (34.9) 14 (30.4)
Hip arthritis, n (%) 26 (20.2) 8 (19.0) 9 (22.5) 9 (19.1)
Intermittent claudication, n (%) 49 (36.6) 17 (39.5) 16 (36.4) 16 (34.0)
Asymptomatic, no exertional leg symptoms, n (%) 8 (6.0) 1 (2.3) 4 (9.1) 3 (6.4)
6-Minute walk distance (m) 320.6 (87.8) 319.9 (85.0) 315.2 (90.1) 326.3 (89.7)
Short physical performance battery (0-12, 12=best), mean (SD) 8.71 (2.41) 8.42 (2.83) 8.57 (2.26) 9.11 (2.10)
Physical activity over 7 days (activity units), mean SD 666 (439) 724 (547) 639 (444) 644 (314)
WIQ distance score, median (IQR) 23.3 (9.4, 43.2) 25.5 (11.6, 43.0) 18.5 (4.2, 46.8) 23.9 (13.6, 40.9)
WIQ speed score, median (IQR) 25.0 (10.9, 39.7) 25.0 (10.9, 32.6) 20.7 (7.6, 37.0) 32.6 (17.4, 46.7)
WIQ stair-climbing score, median (IQR) 37.5 (16.7, 54.2) 41.7 (16.7, 66.7) 29.2 (16.7, 47.9) 41.7 (25.0, 54.2)
Short-form 36 physical functioning score, median (IQR) 40.0 (25.0, 55.0) 40.0 (30.0, 55.0) 35.0 (25.0, 55.0) 35.0 (25.0, 50.0)
Missing data were imputed for individuals who attended a 12-month follow-up visit but did not complete all outcomes at a study visit. IQR indicates interquartile range (25th, 75th
percentiles); WIQ, Walking Impairment Questionnaire.
*Data shown in Table 2 are for all participants who participated in 12-month follow-up testing for at least 1 outcome measure.
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from baseline between PAD participants randomized to
supervised treadmill exercise and those randomized to
control. These results demonstrated that supervised treadmill
exercise did not have a durable benefit on a 6-minute walk
distance in people with PAD.
To our knowledge, this is the only trial to study whether the
beneficial effect of supervised treadmill exercise on the 6-
minute walk distance in people with PAD is durable after the
supervised treadmill exercise intervention has been com-
pleted. However, prior studies have suggested that supervised
treadmill exercise had a persistent benefit on treadmill-
walking performance. The CLEVER (Claudication: Exercise vs.
Endoluminal Revascularization Study) trial randomized 111
participants with PAD and aortoiliac disease to either
supervised treadmill exercise for 6 months, endovascular
revascularization with stenting, or neither therapy.28,29 At 6-
month follow-up, supervised treadmill exercise and revascu-
larization each improved treadmill walking performance more
than control paticipants (within-group mean change from
baseline: +5.8 minutes [SD=4.6], +3.7 minutes [SD=4.9], and
+1.2 minutes [SD=2.6], respectively).28 Between a 6- and 18-
month follow-up, participants in the treadmill exercise group
received telephone calls encouraging exercise but were not
supervised. Among the 79 (71%) of the randomized
Table 3. 12-Month Change in Study Outcomes After a 6-Month Supervised Exercise Intervention
Baseline 12-Mo Follow-Up Within-Group 12-Mo Change
12-Mo Change Compared
to the Attention-Control Group
6-Minute walk test (m)
Supervised treadmill exercise (N=47) 326.3 (89.7) 320.6 (107.1) 5.7 (22.9, +11.5), P=0.52 +7.5 (17.5, +32.6), P=0.56
Supervised resistance training (N=44) 315.2 (90.1) 308.1 (98.9) 7.1 (24.8, +10.6), P=0.43 +6.1 (19.2, +31.4), P=0.64
Attention control group (N=43) 319.9 (85.0) 306.7 (104) 13.2 (31.1, +4.7), P=0.15 Reference
Short physical performance battery (SPPB) (0-12 scale, 12=best)
Supervised treadmill exercise (N=47) 9.11 (2.1) 9.02 (2.62) 0.09 (0.62, +0.45), P=0.76 0.34 (1.13, +0.45), P=0.40
Supervised resistance training (N=44) 8.57 (2.26) 8.75 (2.76) +0.18 (0.39, +0.74), P=0.54 0.08 (0.88, +0.73), P=0.85
Attention control group (N=43) 8.42 (2.83) 8.67 (3.04) +0.26 (0.31, +0.82), P=0.37 Reference
WIQ distance score*
Supervised treadmill exercise (N=47) 23.9 (13.6, 40.9) 37.1 (18.2, 57.4) +11.6 (5.0, +25.7), P=0.040 +4.6 (5.7, +14.9), P=0.38
Supervised resistance training (N=44) 18.5 (4.2, 46.8) 24.0 (10.9, 59.5) +5.8 (0.9, +16.5), P=0.051 +2.6 (6.4, +11.5), P=0.57
Attention control group (N=43) 25.5 (11.6, 43.0) 29.7 (12.5, 59.5) +3.2 (6.4, +24.1), P=0.30 Reference
WIQ speed score*
Supervised treadmill exercise (N=47) 32.6 (17.4, 46.7) 39.1 (25.0, 56.5) +12.0 (4.3, +25.0), P=0.14 +4.6 (5.0, +14.2), P=0.35
Supervised resistance training (N=44) 20.7 (7.6, 37.0) 29.3 (14.1, 49.5) +3.3 (0.0, +25.0), P=0.012 +4.7 (2.6, +12.0), P=0.20
Attention control group (N=43) 25.0 (10.9, 32.6) 32.6 (13.0, 46.7) 0.0 (6.5, +18.5), P=0.37 Reference
WIQ stair-climbing score*
Supervised treadmill exercise (N=47) 41.7 (25.0, 54.2) 54.2 (29.2, 62.5) +8.3 (8.3, +25.0), P=0.27 +7.3 (3.6, +18.2), P=0.19
Supervised resistance training (N=44) 29.2 (16.7, 47.9) 41.7 (29.2, 64.6) +8.3 (12.5, +29.2), P=0.13 +7.3 (3.9, +18.5), P=0.20
Attention control group (N=43) 41.7 (16.7, 66.7) 41.7 (29.2, 62.5) 0.0 (12.5, +16.7), P=0.90 Reference
Short-form-36 physical functioning score*
Supervised treadmill exercise (N=47) 35.0 (25.0, 50.0) 55.0 (40.0, 65.0) +10.0 (5.0, +25.0), P=0.049 +10.0 (+0.7, +19.3), P=0.035
Supervised resistance training (N=44) 35.0 (25.0, 55.0) 45.0 (30.0, 60.0) +5.0 (5.0, +15.0), P=0.24 +5.0 (2.8, +12.8), P=0.21
Attention control group (N=43) 40.0 (30.0, 55.0) 45.0 (30.0, 55.0) 0.0 (15.0, +15.0), P=0.99 Reference
Caltrac accelerometer physical activity
Supervised treadmill exercise (N=47) 643 (314) 528 (318) 115 (264, +35), P=0.13 106 (323, +112), P=0.34
Supervised resistance training (N=44) 637 (441) 673 (484) +37 (125, +198), P=0.66 +46 (181, +272), P=0.69
Attention control group (N=43) 723 (547) 713 (498) 9 (164, +146), P=0.91 Reference
WIQ indicates Walking Impairment Questionnaire.
*Median and interquartile ranges are shown. Estimate (95%CI) and P value are from the combined results for Hodges-Lehmann Estimation. Missing data were imputed for individuals who
attended a 12-month follow-up visit but did not complete all outcomes at a study visit.
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Table 4. Changes From Baseline at 6- and 12-Month Follow-Up in Study Outcomes by Group Assignment Among Participants With
Peripheral Artery Disease
Group
Baseline
Mean (SD)
6-Mo Follow-Up
Mean (SD)
12-Mo Follow-Up
Mean (SD)
6- to 12-Mo Within-Group
Change
6 to 12 Mo Change
Relative to Control
6-Minute walk (m)
Supervised treadmill
exercise (N=47)
326.3 (89.7) 345.2 (83.7) 320.6 (107.1) 24.6 (41.2, 8.0),
P=0.004
28.6 (52.6, 4.5), P=0.020
Supervised resistance
training (N=44)
315.2 (90.1) 312.6 (88.6) 308.1 (98.9) 4.5 (21.4, +12.4),
P=0.60
8.4 (32.7, +15.8), P=0.50
Control group (N=43) 319.9 (85) 302.7 (95.7) 306.7 (104) +4.0 (13.2, +21.1),
P=0.65
Reference
Short physical performance battery
Supervised treadmill
exercise (N=47)
9.11 (2.1) 9.47 (2.02) 9.02 (2.62) 0.45 (0.92, +0.03),
P=0.066
0.05 (0.75, +0.64), P=0.88
Resistance training (N=44) 8.57 (2.26) 9.02 (2.77) 8.75 (2.76) 0.28 (0.78, +0.22),
P=0.28
+0.12 (0.59, +0.83), P=0.74
Control group (N=43) 8.42 (2.83) 9.07 (3.01) 8.67 (3.04) 0.40 (0.89, +0.10),
P=0.12
Reference
WIQ distance score*
Supervised treadmill
exercise (N=47)
23.9 (13.6, 40.9) 47.4 (21.2, 72.3) 37.1 (18.2, 57.4) 0.5 (24.5, +6.7),
P=0.41
8.8 (18.3, +0.6), P=0.066
Resistance training (N=44) 18.5 (4.2, 46.8) 26.5 (10.5, 61.6) 24.0 (10.9, 59.5) 0.0 (6.3, +4.3),
P=0.77
4.5 (11.0, +2.0), P=0.18
Control group (N=43) 25.5 (11.6, 43.0) 27.1 (11.0, 44.6) 29.7 (12.5, 59.5) +3.3 (4.3, +16.0),
P=0.42
Reference
WIQ walking speed score*
Supervised treadmill
exercise (N=47)
32.6 (17.4, 46.7) 43.5 (26.1, 56.5) 39.1 (25.0, 56.5) 0.0 (15.2, +10.9),
P=0.65
1.0 (9.6, +7.6), P=0.81
Resistance training (N=44) 20.7 (7.6, 37.0) 29.3 (10.9, 43.5) 29.3 (14.1, 49.5) 0.0 (6.5, +10.9),
P=0.64
+1.7 (5.0, +8.5), P=0.62
Control group (N=43) 25.0 (10.9, 32.6) 26.1 (14.1, 43.5) 32.6 (13.0, 46.7) 0.0 (7.6, +8.2),
P=0.93
Reference
WIQ stair-climbing score*
Supervised treadmill
exercise (N=47)
41.7 (25.0, 54.2) 41.7 (29.2, 66.7) 54.2 (29.2, 62.5) 0.0 (12.5, +12.5),
P=0.46
1.5 (8.8, +5.9), P=0.70
Resistance training (N=44) 29.2 (16.7, 47.9) 41.7 (25.0, 66.7) 41.7 (29.2, 64.6) 0.0 (12.5, +12.5),
P=0.68
0.4 (8.2, +7.4), P=0.92
Control group (N=43) 41.7 (16.7, 66.7) 41.7 (16.7, 62.5) 41.7 (29.2, 62.5) 0.0 (4.2, +12.5),
P=0.98
Reference
Short-form-36 physical functioning score (0-100 scale, 100=best)*
Supervised treadmill
exercise (N=47)
35.0 (25.0, 50.0) 55.0 (40.0, 75.0) 55.0 (40.0, 65.0) 0.0 (10.0, +10.0),
P=0.42
1.8 (10.3, +6.8), P=0.69
Resistance training (N=44) 35.0 (25.0, 55.0) 50.0 (25.0, 65.0) 45.0 (30.0, 60.0) 5.0 (10.0, +5.0),
P=0.34
3.5 (11.7, +4.7), P=0.40
Control group (N=43) 40.0 (30.0, 55.0) 45.0 (30.0, 55.0) 45.0 (30.0, 55.0) 0.0 (10.0, +10.0),
P=0.82
Reference
Caltrac physical activity
Supervised treadmill
exercise (N=47)
643 (314) 777 (864) 528 (318) 249 (436, 62),
P=0.009
272 (546, +2), P=0.052
Resistance training (N=44) 637 (441) 680 (519) 673 (484) 7 (209, +195),
P=0.94
30 (310, +251), P=0.84
Control group (N=43) 723 (547) 691 (404) 713 (498) +23 (173, +219),
P=0.82
Reference
WIQ indicates Walking Impairment Questionnaire.
*Median and interquartile ranges are shown. Estimate (95%CI) and P value are from the combined results for Hodges-Lehmann Estimation. Data were imputed for individuals who attended
a 12-month follow-up visit but did not complete all outcome measures at each visit.
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participants who completed 18-month follow-up measures,
treadmill walking time remained significantly better in the
supervised treadmill exercise group and in the revascularization
group compared with controls (+5.0 minutes [SD=5.4],
+3.2 minutes [SD=4.7], +0.2 minutes [SD=2.1], respec-
tively).29 A separate study reported that 4 years after complet-
ing a supervised treadmill exercise intervention, few patients
with PAD continued to exercise and that those who stopped
exercising experienced the greatest decline in treadmill walking
ability.30 However, this study was limited by a 50% dropout rate.
The outcomemeasure in these prior trials was treadmill-walking
performance, which is associated with a learning effect.
Therefore, it is possible that the persistent improvement in
treadmill-walking performance may be due to a learning effect
rather than a true long-term benefit in walking endurance.13 In
contrast, the 6-minute walk test is not associated with a
learning effect.13 Therefore, persistent improvement in the 6-
minute walk is more likely to represent a meaningful persistent
improvement in walking endurance. The lack of persistent
benefit in 6-minute walk performance is important because the
corridor walking measured during the 6-minute walk test is
more relevant to walking during daily life.13
The WIQ distance score significantly improved in the
supervised treadmill group at 6-month follow-up, but this
effect did not persist at 12-month follow-up. However, the
SF-36 physical functioning score was significantly better in
the supervised treadmill exercise group compared with the
control group at 12-month follow-up, suggesting that those
randomized to supervised treadmill exercise perceived benefit
at 12-month follow-up, even though their 6-minute walk
distance was not better at 12-month follow-up compared to
the control group.
In contrast to findings reported here for the 6-minute walk,
a previous study showed that a home-based walking exercise
intervention had a durable benefit on change in 6-minute walk
distance in people with PAD.30 The GOALS (Group Oriented
Arterial Leg Study) trial randomized 194 participants with PAD
to a group-mediated cognitive behavioral intervention
designed to encourage home-based exercise, versus an
attention control group.30 After 6-months of weekly on-site
meetings with the study coach and other participants with
PAD, the 6-minute walk distance significantly improved by
53.5 m in the intervention group, relative to the control
group.30 Between 6- and 12-month follow-up, PAD
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Figure 2. Change over time in 6-minute walk and the short physical performance battery after a 6-month supervised treadmill exercise
intervention in peripheral artery disease (N=134). A, 6-minute walk distance. B, Short physical performance battery (SPPB) scores.
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participants received only telephone calls encouraging them
to continue exercise. At 12-month follow-up, participants
randomized to exercise continued to have a significantly
greater improvement from baseline in 6-minute walk distance
by +34.1 m 6 months after the intensive phase of the
intervention had been completed, relative to the control
group.30
There are several potential explanations for why supervised
treadmill exercise did not have a sustained benefit on
improving the 6-minute walk distance in people with PAD.
First, supervised treadmill exercise has a more potent effect on
improving treadmill-walking distance than on improving the
6-minute walk distance.3,4,13,31,32 In people with PAD, super-
vised treadmill exercise improves the 6-minute walk by 31 m
compared with a nonexercising control group, whereas home-
based exercise improves the 6-minute walk by 50 to 55 m
compared with a nonexercising control group.3,4,31,32 This less
potent effect of supervised treadmill exercise on change in
6-minute walk distance may result in a less durable benefit of
supervised treadmill exercise on change in 6-minute walk.
Second, supervised treadmill exercise is difficult for many PAD
patients to continue once the supervised treadmill exercise
intervention is completed. Third, supervised treadmill exercise
improves treadmill-walking performance in part because of a
learning effect,13 and this learning effect may be durable,
resulting in a persistently improved treadmill-walking distance,
even after the supervised treadmill exercise intervention has
been completed. In contrast, supervised treadmill exercise
does not confer a learning effect on the 6-minute walk test.
Therefore, a 6-minute walk distance may be a more direct
measure of walking endurance, which may decline after
supervised treadmill exercise is completed. Findings reported
here are consistent with prior data suggesting that 6-minute
walk performance and treadmill-walking performance should
not be considered interchangeable measures of walking
endurance in people with PAD.33 Fourth, a decline in physical
activity level observed in the supervised treadmill exercise
group between 6- and 12-month follow-up that was nearly
statistically significant compared with the control group may
have contributed to the decline in the 6-minute walk distance
observed in this group after the supervised treadmill exercise
intervention ended.
This study has limitations. First, this trial did not repeat
treadmill exercise testing at 12-month follow-up. Therefore, it
could not determine whether the improvement in treadmill-
walking performance observed at the 6-month follow-up was
maintained at 12 months.3 Second, 10 participants who
completed a 6-month follow-up did not complete the 12-
month follow-up testing. However, data were imputed for the
participants who provided data for at least one 12-month
follow-up measure.
Conclusion
A supervised treadmill exercise intervention that significantly
improved the 6-minute walk distance at a 6-month follow-up3
did not have a durable benefit on that 6-minute walk perfor-
mance 6 months after the treadmill exercise intervention was
completed. These results do not support a persistent beneficial
effect of supervised treadmill exercise on the 6-minute walk
distance in patients with PAD.
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Table S1. Twelve-month change in study outcomes after a six-month supervised exercise intervention.*  
 Baseline 12-month follow-up Within group 12-month 
change 
12-month change compared to the 
attention control group 
Six-minute walk test (meters) 
Supervised treadmill exercise 
(N=43) 
334.1 (79.9) 332.2 (96.1) -1.9 (-19.6, +15.7) 
P=0.83 
+12.6 (-12.7, +37.9) 
P=0.33 
Supervised resistance training 
(N=43) 
318.3 (88.8) 312.5 (95.2) -5.8 (-23.4, +11.9) 
P=0.52 
+8.8 (-16.5, +34.0) 
P=0.49 
Attention control group (N=41) 322.3 (85.0) 307.8 (103.8) -14.5 (-32.6, +3.6) 
P=0.11 
Reference 
Short Physical Performance Battery (SPPB) (0-12 scale, 12=best) 
Supervised treadmill exercise 
(N=47) 
9.11 (2.10) 9.02 (2.62) -0.09 (-0.63, +0.46)  
P=0.76 
-0.34 (-1.13, +0.44) 
P=0.39 
Supervised resistance training 
(N=43) 
8.67 (2.17) 8.81 (2.74) +0.14 (-0.43, +0.71)  
P=0.63 
-0.12 (-0.92, +0.69)  
P=0.77 
Attention control group (N=43) 8.42 (2.83) 8.67 (3.04) +0.26 (-0.31, +0.82)  
P=0.37 
Reference 
Walking Impairment Questionnaire Distance Score* 
Supervised treadmill exercise 
(N=37) 
22.2 (13.6, 37.1) 37.1 (18.2, 55.3) +11.6 (-4.3, +27.7)  
P=0.004 
+5.8 (-7.6, +15.9) 
P=0.43 
Supervised resistance training 
(N=37) 
18.5 (4.2, 47.3) 24.0 (10.9, 55.3) +5.8 (-0.9, +15.8)  
P=0.007 
+1.7 (-9.2, +11.0) 
P=0.73 
Attention control group (N=28) 28.3 (13.4, 43.3) 35.9 (12.6, 59.5) +1.8 (-6.2, +24.6)  
P=0.12 
Reference 
Analyses using original data without imputation.  
 
 
Table S1 (continued). Twelve-month change in study outcomes after a six-month supervised exercise intervention.* 
 Baseline 12-month follow-up Within group 12-month 
change 
12-month change compared to the 
attention control group 
WIQ Speed Score* 
Supervised treadmill exercise 
(N=40) 
25.0 (14.1, 45.1) 42.9 (25.0, 58.7) +14.1 (-2.2, +25.0)  
P=0.005 
+6.5 (-3.3, +17.4) 
P=0.17 
Supervised resistance training 
(N=37) 
21.7 (7.6, 37.0) 28.3 (10.9, 43.5) +3.3 (0.0, +21.7)  
P=0.002 
+3.3 (-3.3, +10.9)  
P=0.40 
Attention control group (N=30) 25.0 (10.9, 32.6) 35.9 (17.4, 46.7) 0.0 (-5.4, +18.5)  
P=0.15 
Reference 
WIQ Stair Climbing Score* 
Supervised treadmill exercise 
(N=38) 
39.6 (20.8, 50.0) 54.2 (33.3, 62.5) +10.4 (-4.2, +29.2)  
P=0.020 
+8.3 (-4.2, +16.7)  
P=0.31 
Supervised resistance training 
(N=37) 
29.2 (16.7, 45.8) 41.7 (29.2, 62.5) +8.3 (-8.3, +25.0)  
P=0.031 
+4.2 (-8.3, +16.7)  
P=0.40 
Attention control group (N=31) 41.7 (16.7, 66.7) 41.7 (29.2, 66.7) 0.0 (-12.5, +20.8)  
P=0.31 
Reference 
Short-Form-36 Physical Functioning Score* 
Supervised treadmill exercise 
(N=41) 
35.0 (25.0, 50.0) 55.0 (40.0, 65.0) +10.0 (0.0, +25.0)  
P<0.001 
+10.0 (0.0, +20.0)  
P=0.014 
Supervised resistance training 
(N=35) 
35.0 (25.0, 55.0) 45.0 (30.0, 60.0) +10.0 (-5.0, +15.0)  
P=0.001 
+10.0 (0.0, +20.0)  
P=0.039 
Attention control group (N=32) 45.0 (30.0, 55.0) 40.0 (30.0, 57.5) 0.0 (-15.0, +12.5)  
P=0.93 
Reference 
Caltrac Accelerometer Physical Activity 
Supervised treadmill exercise 
(N=37) 
696 (316) 534 (304) -162 (-331, +7)  
P=0.06 
-167 (-412, +77) 
P=0.18 
Supervised resistance training 
(N=32) 
542 (401) 545 (398) +3 (-179, +185)  
P=0.97 
-2 (-255, +251)  
P=0.99 
Attention control group (N=34) 753 (585) 759 (529) +5 (-171, +182)  
P=0.95 
Reference 
* Median and interquartile ranges are shown. Estimate (95% CI) and P value are from the results for Hodges-Lehmann Estimation.   
  
 
 
Table S2. Changes from baseline at six and twelve-month follow-up in study outcomes by group assignment among 
participants with peripheral artery disease. * 
Group Baseline 
Mean (SD) 
6-month 
follow-up 
Mean (SD) 
12-month follow-
up Mean (SD) 
6 to 12-month 
within group 
change 
6 to 12 month 
change relative 
to control 
Six-minute walk (meters) 
Supervised treadmill 
exercise (N=43) 
334.1 (79.9) 355.6 (67.2) 332.2 (96.1) -23.5  
(-40.3, -6.6) 
P=0.007 
-26.6  
(-50.7, -2.5) 
P=0.031 
Supervised resistance 
training (N=43) 
318.3 (88.8) 314.1 (89.1) 312.5 (95.2) -1.5  
(-18.4, +15.3) 
P=0.86 
-4.6  
(-28.8, +19.5) 
P=0.70 
Control group (N=41) 322.3 (85.0) 304.7 (95.6) 307.8 (103.8) +3.1  
(-14.2, +20.4) 
P=0.72 
Reference  
Short physical performance battery 
Supervised treadmill 
exercise (N=47) 
9.11 (2.10) 9.47 (2.02) 9.02 (2.62) -0.45  
(-0.92, +0.03) 
P=0.07 
-0.05  
(-0.74, +0.64) 
P=0.88 
Resistance training 
(N=43) 
8.67 (2.17) 9.05 (2.80) 8.81 (2.74) -0.23  
(-0.73, +0.27) 
P=0.36 
+0.16  
(-0.54, +0.87) 
P=0.65 
Control group 
(N=43) 
8.42 (2.83) 9.07 (3.01) 8.67 (3.04) -0.40  
(-0.89, +0.10) 
P=0.12 
Reference 
 
  
 
 
Table S2 (continued):  Changes from baseline at six and twelve-month follow-up in study outcomes by group assignment 
among participants with peripheral artery disease.* 
Group Baseline 
Median 
(Interquartile 
range) 
6-month 
follow-up 
Median 
(Interquartile 
range) 
12-month follow-
up  Median 
(Interquartile 
range) 
6 to 12-month 
within group 
change 
Median 
(Interquartile 
range) 
6 to 12 month 
change 
relative to 
control 
WIQ Distance Score* 
Supervised 
treadmill exercise 
(N=37) 
22.2 (13.6, 37.1) 37.1 (16.9, 61.6) 37.1 (18.2, 55.3) +0.8  
(-22.4, +8.5) 
P=0.66 
-3.2  
(-15.6, +5.3) 
P=0.46 
Resistance training 
(N=37) 
18.5 (4.2, 47.3) 26.5 (10.5, 61.5) 24.0 (10.9, 55.3) 0.0  
(-4.6, +2.8)  
P=0.55 
-2.5  
(-10.1, +2.6) 
P=0.35 
Control group 
(N=28) 
28.3 (13.4, 43.3) 28.9 (11.8, 48.9) 35.9 (12.6, 59.5) 0.0 (-5.1, +11.4)  
P=0.40 
Reference  
WIQ Walking Speed Score* 
Supervised 
treadmill exercise 
(N=40) 
25.0 (14.1, 45.1) 40.8 (25.5, 54.3) 42.9 (25.0, 58.7) 0.0 (-14.1, 10.9) 
P=0.95 
0.0 (-7.6, 10.9) 
P=0.82 
Resistance training 
(N=37) 
21.7 (7.6, 37.0) 25.0 (10.9, 43.5) 28.3 (10.9, 43.5) 0.0  
(-6.5, +10.9)  
P=0.41 
+1.1  
(-4.3, +8.7) 
P=0.53 
Control group 
(N=30) 
25.0 (10.9, 32.6) 25.5 (14.1, 50.0) 35.9 (17.4, 46.7) 0.0 (-7.6, +7.6)  
P=0.98 
Reference  
WIQ Stair Climbing Score* 
Supervised 
treadmill exercise 
(N=38) 
39.6 (20.8, 50.0) 41.7 (29.2, 66.7) 54.2 (33.3, 62.5) 0.0  
(-8.3, +12.5)  
P=0.85 
-4.2  
(-12.5, 0.0) 
P=0.21 
Resistance training 
(N=37) 
29.2 (16.7, 45.8) 45.8 (29.2, 66.7) 41.7 (29.2, 62.5) 0.0 
 (-12.5, +8.3)  
P=0.38 
-4.2  
(-16.7, 0.0) 
P=0.11 
Control group 
(N=31) 
41.7 (16.7, 66.7) 37.5 (16.7, 66.7) 41.7 (29.2, 66.7) 0.0 (0.0, +12.5) 
P=0.07 
Reference  
 
 
 
Table S2 (Continued). Changes from baseline at six and twelve-month follow-up in study outcomes by group assignment 
among participants with peripheral artery disease.* 
Group Baseline 
Mean (SD) 
6-month 
follow-up 
Mean (SD) 
12-month 
follow-up 
Mean (SD) 
6 to 12-month 
within group 
change 
6 to 12 month 
change 
relative to 
control 
Short-Form 36 Physical Functioning Score (0-100 scale, 100=best)* 
Supervised 
treadmill exercise 
(N=41) 
35.0  
(25.0, 50.0) 
55.0  
(40.0, 70.0) 
55.0  
(40.0, 65.0) 
0.0  
(-10.0, +10.0)  
P=0.74 
0.0  
(-5.0, +10.0) 
P=0.92 
Resistance training 
(N=35) 
35.0  
(25.0, 55.0) 
50.0  
(25.0, 70.0) 
45.0  
(30.0, 60.0) 
-5.0  
(-10.0, +5.0)  
P=0.19 
0.0 
(-10.0, +5.0) 
P=0.64 
Control group 
(N=32) 
45.0  
(30.0, 55.0) 
45.0  
(32.5, 55.0) 
40.0  
(30.0, 57.5) 
0.0  
(-15.0, +7.5)  
P=0.66 
Reference  
Caltrac (accelerometer) measured physical activity 
Supervised 
treadmill exercise 
(N=37) 
696 (316) 850 (940) 534 (304) -316  
(-530, -102) 
P=0.004 
-398  
(-708, -88) 
P=0.012 
Resistance training 
(N=32) 
542 (401) 561 (423) 545 (398) -16  
(-247, +214) 
P=0.89 
-98  
(-419, +223) 
P=0.55 
Control group 
(N=34) 
753 (585) 677 (410) 759 (529) +82  
(-141, +306) 
P=0.47 
Reference  
* Median and interquartile ranges are shown. Estimate (95% CI) and P value are from the results for Hodges-Lehmann Estimation.   
